LDL Particle Number Measured Using NMR Clinical Analyzer
|
By LabMedica International staff writers Posted on 25 Aug 2014 |
|
Image: The Vantera Clinical Analyzer offers the technology that has the ability to directly enumerate low-density lipoprotein (LDL) particle numbers (Photo courtesy of LipoScience).
Fully-automated high-throughput nuclear magnetic resonance (NMR) spectroscopy has been developed to enable measurements in a clinical laboratory setting.
NMR-measured low-density lipoprotein particle number (LDL-P) has been shown to be more strongly associated with cardiovascular disease outcomes than LDL cholesterol (LDL-C) in individuals for whom these alternate measures of LDL are discordant.
Scientists at LipoScience Inc. (Raleigh, NC, USA) purchased serum pools and controls from Solomon Park Research Laboratories (Kirkland, WA, USA). Controls were prepared by identifying serum samples with high and low lipoprotein ranges. Additional serum pools were prepared in-house from donor subjects identified at LipoScience or Mayo Clinic (Rochester, MN, USA). NMR spectra were acquired on the NMR Profiler (Bruker Bio-Spin; Billerica, MA, USA) or the Vantera Clinical Analyzer (Agilent Technologies; Santa Clara, CA, USA), both equipped with 400 MHz 1H NMR spectrometers.
The sensitivity and linearity were established within the range of 300–3,500 nmol/L. For serum pools containing low, medium and high levels of LDL-P, the inter-assay, intra-assay precision and repeatability gave coefficients of variation (CVs) between 2.6 and 5.8%. The reference interval was determined to be 457–2,282 nmol/L and the assay was compatible with multiple specimen collection tubes. Of 30 substances tested, only two exhibited the potential for assay interference. Moreover, the LDL-P results from samples run on two NMR platforms, Vantera Clinical Analyzer and NMR Profiler, showed excellent correlation.
The authors concluded that the successful development of a method to measure LDL-P on a fully automated platform allows NMR technology dissemination into the routine, clinical laboratory setting and creates the opportunity for NMR-based testing across a broader range of clinical applications. They point out that, several leading national reference laboratories and large hospital system laboratories have successfully integrated the Vantera into their clinical laboratory operations. The study was published on July 28, 2014, in the journal Clinical Biochemistry.
Related Links:
LipoScience Inc.
Mayo Clinic
Bruker Bio-Spin
NMR-measured low-density lipoprotein particle number (LDL-P) has been shown to be more strongly associated with cardiovascular disease outcomes than LDL cholesterol (LDL-C) in individuals for whom these alternate measures of LDL are discordant.
Scientists at LipoScience Inc. (Raleigh, NC, USA) purchased serum pools and controls from Solomon Park Research Laboratories (Kirkland, WA, USA). Controls were prepared by identifying serum samples with high and low lipoprotein ranges. Additional serum pools were prepared in-house from donor subjects identified at LipoScience or Mayo Clinic (Rochester, MN, USA). NMR spectra were acquired on the NMR Profiler (Bruker Bio-Spin; Billerica, MA, USA) or the Vantera Clinical Analyzer (Agilent Technologies; Santa Clara, CA, USA), both equipped with 400 MHz 1H NMR spectrometers.
The sensitivity and linearity were established within the range of 300–3,500 nmol/L. For serum pools containing low, medium and high levels of LDL-P, the inter-assay, intra-assay precision and repeatability gave coefficients of variation (CVs) between 2.6 and 5.8%. The reference interval was determined to be 457–2,282 nmol/L and the assay was compatible with multiple specimen collection tubes. Of 30 substances tested, only two exhibited the potential for assay interference. Moreover, the LDL-P results from samples run on two NMR platforms, Vantera Clinical Analyzer and NMR Profiler, showed excellent correlation.
The authors concluded that the successful development of a method to measure LDL-P on a fully automated platform allows NMR technology dissemination into the routine, clinical laboratory setting and creates the opportunity for NMR-based testing across a broader range of clinical applications. They point out that, several leading national reference laboratories and large hospital system laboratories have successfully integrated the Vantera into their clinical laboratory operations. The study was published on July 28, 2014, in the journal Clinical Biochemistry.
Related Links:
LipoScience Inc.
Mayo Clinic
Bruker Bio-Spin
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Human Estradiol Assay
Human Estradiol CLIA Kit
Gold Member
Hematology Analyzer
Medonic M32B
Latest Clinical Chem. News
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
- Prostate Cancer Markers Based on Chemical Make-Up of Calcifications to Speed Up Detection
- Breath Test Could Help Detect Blood Cancers
- ML-Powered Gas Sensors to Detect Pathogens and AMR at POC
- Saliva-Based Cancer Detection Technology Eliminates Need for Complex Sample Preparation
Channels
Molecular Diagnostics
view channel
Sample Prep Instrument to Empower Decentralized PCR Testing for Tuberculosis
Tuberculosis remains the deadliest infectious disease worldwide despite being both treatable and curable when diagnosed early. A major barrier to timely diagnosis is that PCR-based TB testing is still... Read more
Endometriosis Blood Test Could Replace Invasive Laparoscopic Diagnosis
Endometriosis affects an estimated 1 in 10 women globally, yet diagnosis can take 7 to 10 years on average due to the invasive nature of laparoscopy and lack of accurate, non-invasive tests.... Read more
World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device
Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more
Rapid Diagnostic Breakthrough Simultaneously Detects Resistance and Virulence in Klebsiella Pneumoniae
Antibiotic resistance is a steadily escalating threat to global healthcare, making common infections harder to treat and increasing the risk of severe complications. One of the most concerning pathogens... Read moreHematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
Colon cancer remains a major cause of cancer-related illness, with many patients facing relapse even after surgery and chemotherapy. Up to 40% of people with stage III disease experience recurrence, highlighting... Read more
Microbiology
view channel
New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Urinary tract infections affect around 152 million people every year, making them one of the most common bacterial infections worldwide. In routine medical practice, diagnosis often relies on rapid urine... Read more
Breakthroughs in Microbial Analysis to Enhance Disease Prediction
Microorganisms shape human health, ecosystems, and the planet’s climate, yet identifying them and understanding how they are related remains a major scientific challenge. Even with modern DNA sequencing,... Read more
Pathology
view channel
AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. Monitoring these cancers for recurrence or relapse typically relies on tissue... Read more
Technology
view channel
AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
Colorectal cancer is one of the most common and deadly cancers worldwide, and accurately predicting patient survival remains a major clinical challenge. Traditional prognostic tools often rely on either... Read more
Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
Glioblastoma is one of the most aggressive and fatal brain cancers, with most patients surviving less than two years after diagnosis. Treatment is particularly challenging because the tumor infiltrates... Read more
Industry
view channel
BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) has entered into a strategic collaboration with the Institute for Immunology and Immune Health (I3H, Philadelphia, PA, USA) at the University... Read more
